GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
GO:0009895111 | Esophagus | ESCC | negative regulation of catabolic process | 201/8552 | 320/18723 | 3.88e-10 | 1.05e-08 | 201 |
GO:0031330111 | Esophagus | ESCC | negative regulation of cellular catabolic process | 166/8552 | 262/18723 | 5.17e-09 | 1.08e-07 | 166 |
GO:001050712 | Esophagus | ESCC | negative regulation of autophagy | 56/8552 | 85/18723 | 1.34e-04 | 9.09e-04 | 56 |
GO:001050621 | Liver | HCC | regulation of autophagy | 210/7958 | 317/18723 | 7.59e-18 | 8.45e-16 | 210 |
GO:000989522 | Liver | HCC | negative regulation of catabolic process | 196/7958 | 320/18723 | 7.98e-12 | 3.35e-10 | 196 |
GO:003133022 | Liver | HCC | negative regulation of cellular catabolic process | 164/7958 | 262/18723 | 3.52e-11 | 1.35e-09 | 164 |
GO:00105074 | Liver | HCC | negative regulation of autophagy | 57/7958 | 85/18723 | 4.10e-06 | 5.27e-05 | 57 |
GO:001050610 | Oral cavity | OSCC | regulation of autophagy | 198/7305 | 317/18723 | 1.63e-17 | 1.51e-15 | 198 |
GO:000989519 | Oral cavity | OSCC | negative regulation of catabolic process | 180/7305 | 320/18723 | 2.44e-10 | 6.86e-09 | 180 |
GO:003133020 | Oral cavity | OSCC | negative regulation of cellular catabolic process | 152/7305 | 262/18723 | 3.04e-10 | 8.28e-09 | 152 |
GO:00105075 | Oral cavity | OSCC | negative regulation of autophagy | 51/7305 | 85/18723 | 7.08e-05 | 5.62e-04 | 51 |
GO:001050615 | Oral cavity | LP | regulation of autophagy | 132/4623 | 317/18723 | 1.82e-11 | 1.28e-09 | 132 |
GO:0009895110 | Oral cavity | LP | negative regulation of catabolic process | 128/4623 | 320/18723 | 8.36e-10 | 3.91e-08 | 128 |
GO:0031330110 | Oral cavity | LP | negative regulation of cellular catabolic process | 107/4623 | 262/18723 | 5.25e-09 | 2.16e-07 | 107 |
GO:001050711 | Oral cavity | LP | negative regulation of autophagy | 38/4623 | 85/18723 | 4.36e-05 | 6.24e-04 | 38 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAGEA6 | SNV | Missense_Mutation | novel | c.185N>T | p.Pro62Leu | p.P62L | P43360 | protein_coding | tolerated(0.25) | benign(0.159) | TCGA-E6-A2P9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAGEA6 | SNV | Missense_Mutation | novel | c.796C>A | p.Pro266Thr | p.P266T | P43360 | protein_coding | deleterious(0.02) | probably_damaging(0.96) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAGEA6 | SNV | Missense_Mutation | novel | c.83N>T | p.Ala28Val | p.A28V | P43360 | protein_coding | tolerated(0.2) | benign(0.159) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
MAGEA6 | SNV | Missense_Mutation | novel | c.614T>G | p.Ile205Ser | p.I205S | P43360 | protein_coding | deleterious(0) | possibly_damaging(0.723) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAGEA6 | insertion | In_Frame_Ins | novel | c.175_176insACT | p.Pro59delinsHisSer | p.P59delinsHS | P43360 | protein_coding | | | TCGA-BG-A0MS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
MAGEA6 | insertion | In_Frame_Ins | novel | c.175_176insTAACACACT | p.Pro59delinsLeuThrHisSer | p.P59delinsLTHS | P43360 | protein_coding | | | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAGEA6 | insertion | In_Frame_Ins | novel | c.175_176insTAACACACT | p.Pro59delinsLeuThrHisSer | p.P59delinsLTHS | P43360 | protein_coding | | | TCGA-D1-A0ZP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
MAGEA6 | SNV | Missense_Mutation | | c.698G>T | p.Gly233Val | p.G233V | P43360 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-G3-A6UC-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
MAGEA6 | SNV | Missense_Mutation | novel | c.82G>T | p.Ala28Ser | p.A28S | P43360 | protein_coding | tolerated(0.06) | possibly_damaging(0.799) | TCGA-G3-A6UC-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
MAGEA6 | SNV | Missense_Mutation | novel | c.83N>T | p.Ala28Val | p.A28V | P43360 | protein_coding | tolerated(0.2) | benign(0.159) | TCGA-GJ-A3OU-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |